Your account is not claimed yet. You can sign up with ORCID to claim your account.

David S Siegel (D S Siegel, David Siegel)

ORCID

Publication Activity (10 Years)

Years Active: 2014-2023
Publications (10 Years): 15

Top Venues

The New England journal of medicine

Leukemia & lymphoma

Blood cancer journal

British journal of haematology

New York University (PHD)

This page only lists publications with an associated author ORCID identifier.

Education History

New York University

United States

PHD :: Basic Medical Sciences

Publications

Yi Lin, Noopur S Raje, Jesus G Berdeja, David S Siegel, Sundar Jagannath, Deepu Madduri, Michaela Liedtke, Jacalyn Rosenblatt, Marcela V Maus, Monica Massaro, Fabio Petrocca, Ashish Yeri, Olivia Finney, Andrea Caia, Zhihong Yang, Nathan Martin, Timothy B Campbell, Julie Rytlewski, Jaymes Fuller, Kristen Hege, Nikhil C Munshi, James N Kochenderfer
Idecabtagene vicleucel for relapsed and refractory multiple myeloma: post hoc 18-month follow-up of a phase 1 trial. Nature medicine (2023)
Saad Z Usmani, Hang Quach, Maria-Victoria Mateos-Manteca, Carl Ola Landgren, Xavier Leleu, David S Siegel, Katja C Weisel, Xiaomei Shu, Chuang Li, Meletios A Dimopoulos
Final Analysis of Carfilzomib, Dexamethasone, and Daratumumab Versus Carfilzomib and Dexamethasone in the CANDOR Study. Blood advances (2023)
Sarvarinder K Gill, Rashmi Unawane, Shuqi Wang, Jaeil Ahn, Adolfo Aleman, David S Siegel, David H Vesole, Harsh Parmar, Pooja Phull, Noa Biran
I-OPen: inferior outcomes of penta-refractory compared to penta-exposed multiple myeloma patients. Blood cancer journal 12 (9) (2022)
Nizar J Bahlis, David S Siegel, Gary J Schiller, Christy Samaras, Michael Sebag, Jesus Berdeja, Siddhartha Ganguly, Jeffrey Matous, Kevin Song, Christopher S Seet, Mirelis Acosta-Rivera, Michael Bar, Donald Quick, Bertrand Anz, Gustavo Fonseca, Weiyuan Chung, Kim Lee, Jorge Mouro, Amit Agarwal, Donna Reece
Pomalidomide, dexamethasone, and daratumumab immediately after lenalidomide-based treatment in patients with multiple myeloma: updated efficacy, safety, and health-related quality of life results from the phase 2 MM-014 trial. Leukemia & lymphoma 63 (6) (2022)
Manpreet Bariana, Elena Cassella, Janice Rateshwar, Samedy Ouk, Hsiou-Chi Liou, Claudia Heller, Iriana Colorado, Rena Feinman, Ali Makhdoom, David S Siegel, Glenn Heller, Andrea Tuckett, Patrizia Mondello, Johannes L Zakrzewski
Inhibition of NF-κB DNA Binding Suppresses Myeloma Growth via Intracellular Redox and Tumor Microenvironment Modulation. Molecular cancer therapeutics 21 (12) (2022)
Daniel Auclair, Carol A Mansfield, Mark A Fiala, Ajai Chari, Craig E Cole, Jonathan L Kaufman, Gregory J Orloff, David S Siegel, Jeffrey A Zonder, Brennan Mange, Jennifer Yesil, Mehul Dalal, Joseph R Mikhael
Preferences and Priorities for Relapsed Multiple Myeloma Treatments Among Patients and Caregivers in the United States. Patient preference and adherence 16 (2022)
Kimberley Doucette, Neil J Shah, Michele L Donato, David S Siegel, Scott D Rowley, David H Vesole
Immune tolerance with combined allogeneic haplo-identical haematopoietic stem cell transplant and renal transplant. British journal of haematology 194 (4) (2021)
David S Siegel, Katja Weisel, Anita Zahlten-Kumeli, Rohan Medhekar, Bifeng Ding, Xavier Leleu
Health-related quality of life outcomes from the CANDOR study in patients with relapsed or refractory multiple myeloma. Leukemia & lymphoma 62 (12) (2021)
Noa Biran, Elli Gourna Paleoudis, Rena Feinman, David H Vesole, Joshua Zenreich, Shuqi Wang, Jaeil Ahn, Meena Bansal, Scott Douglas Rowley, Michele L Donato, Andrew L Pecora, Joshua Richter, Palka Anand, Laura McBride, Kristin Ivanovski, Robert Korngold, David S Siegel
Pembrolizumab, lenalidomide and dexamethasone post autologous transplant in patients with high-risk multiple myeloma. American journal of hematology 96 (11) (2021)
Noa Biran, Wanting Zhai, Roxanne E Jensen, Jeanne S Mandelblatt, Susan Kumka, Rashmi Unawane, Kristi D Graves, David H Vesole, David S Siegel, Arnold L Potosky
Patient-reported outcomes following autologous stem cell transplant for patients with multiple myeloma. EJHaem 2 (3) (2021)
Nikhil C Munshi, Larry D Anderson, Nina Shah, Deepu Madduri, Jesús Berdeja, Sagar Lonial, Noopur Raje, Yi Lin, David S Siegel, Albert Oriol, Philippe Moreau, Ibrahim Yakoub Agha, Michel Delforge, Michele Cavo, Hermann Einsele, Hartmut Goldschmidt, Katja Weisel, Alessandro Rambaldi, Donna Reece, Fabio Petrocca, Monica Massaro, Jamie N Connarn, Shari Kaiser, Payal Patel, Liping Huang, Timothy B Campbell, Kristen Hege, Jesús San-Miguel
Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma. The New England journal of medicine 384 (8) (2021)
William E Pierceall, Michael D Amatangelo, Nizar J Bahlis, David S Siegel, Adeeb Rahman, Oliver Van Oekelen, Paola Neri, Mary Young, Weiyuan Chung, Natalya Serbina, Samir Parekh, Amit Agarwal, Anjan Thakurta
Immunomodulation in Pomalidomide, Dexamethasone, and Daratumumab-Treated Patients with Relapsed/Refractory Multiple Myeloma. Clinical cancer research : an official journal of the American Association for Cancer Research 26 (22) (2020)
Maria Gavriatopoulou, Ajai Chari, Christine Chen, Nizar Bahlis, Dan T Vogl, Andrzej Jakubowiak, David Dingli, Robert F Cornell, Craig C Hofmeister, David S Siegel, Jesus G Berdeja, Donna Reece, Darrell White, Suzanne Lentzsch, Cristina Gasparetto, Carol Ann Huff, Sundar Jagannath, Rachid Baz, Ajay K Nooka, Joshua Richter, Rafat Abonour, Terri L Parker, Andrew J Yee, Philippe Moreau, Sagar Lonial, Sascha Tuchman, Katja C Weisel, Mohamad Mohty, Sylvain Choquet, T J Unger, Kai Li, Yi Chai, Lingling Li, Jatin Shah, Sharon Shacham, Michael G Kauffman, Meletios Athanasios Dimopoulos
Integrated safety profile of selinexor in multiple myeloma: experience from 437 patients enrolled in clinical trials. Leukemia 34 (9) (2020)
Noopur Raje, Jesus Berdeja, Yi Lin, David S Siegel, Sundar Jagannath, Deepu Madduri, Michaela Liedtke, Jacalyn Rosenblatt, Marcela V Maus, Ashley Turka, Lyh-Ping Lam, Richard A Morgan, Kevin Friedman, Monica Massaro, Julie Wang, Greg Russotti, Zhihong Yang, Timothy Campbell, Kristen Hege, Fabio Petrocca, M Travis Quigley, Nikhil Munshi, James N Kochenderfer
Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma. The New England journal of medicine 380 (18) (2019)
David S Siegel, Gary J Schiller, Kevin W Song, Richy Agajanian, Keith Stockerl-Goldstein, Hakan Kaya, Michael Sebag, Christy Samaras, Ehsan Malek, Giampaolo Talamo, Christopher S Seet, Jorge Mouro, William E Pierceall, Faiza Zafar, Weiyuan Chung, Shankar Srinivasan, Amit Agarwal, Nizar J Bahlis
Pomalidomide plus low-dose dexamethasone in relapsed refractory multiple myeloma after lenalidomide treatment failure. British journal of haematology 188 (4) (2019)
David S Siegel, P Richardson, M Dimopoulos, P Moreau, C Mitsiades, D Weber, J Houp, C Gause, S Vuocolo, J Eid, T Graef, K C Anderson
Vorinostat in combination with lenalidomide and dexamethasone in patients with relapsed or refractory multiple myeloma. Blood cancer journal 4 (2014)

David S Siegel.css-eqlu8i{font-size:small;padding-left:4px;} (D S Siegel, David Siegel)

Publication Activity (10 Years)

Top Topics

Top Venues

David S Siegel (D S Siegel, David Siegel)